Aspira Diagnostics

Mumbai, India Founded: 2015 • Age: 11 yrs Listed
Pathology lab services are operated through a chain of facilities.

About Aspira Diagnostics

Aspira Diagnostics is a publicly listed company based in Mumbai (India) founded in 2015. Pathology lab services are operated through a chain of facilities. The company has 70 employees. Its chief executive, as recorded, is Chander Puri. Its Indian entity Aspira Pathlab & Diagnostics Limited reported revenue of ₹25.50 Cr. Aspira Diagnostics offers products and services including Pathology Test, Sonography, X-Ray, and Health Packages. Its focus areas include Clinical Laboratory Chains and Pathology. Similar companies include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics; 3 of its 3 listed similar companies have raised funding.

Company details

Aspira was founded in 2015 and is based in Mumbai, India. The company operates as a chain of pathology labs focused on diagnostic services. Core activities include laboratory testing and pathology diagnostics, with operations centered in the healthcare sector. The domain aspiradiagnostics.com is used for its online presence. Leadership is provided by CEO Chander Puri.

  • Headquarters Mumbai, India
  • Employees 70
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    •••• ••••
  • Website aspiradiagnostics.com
  • Social LinkedIn X Facebook Instagram
  • Legal Name Aspira Pathlab & Diagnostics Ltd.
Operational Areas
Key Metrics
  • Market Cap
    ₹135 Cr

    ASPIRA · BSE

  • Share Price
    ₹137.55

    +5.00% today

  • Revenue
    ₹22.00 Cr

    FY 2024-25 · +66.7% YoY

  • EBITDA
    ₹3.47 Cr

    Margin 15.8%

  • Net Profit
    ₹2.05 Cr

    FY 2024-25 · +176.2% YoY

  • P/E (TTM)
    55.4x

    P/B 18.4x

  • ROE
    16.5%

    ROCE 11.5%

  • Debt / Equity
    0.15

    Interest cover 17.7x

  • Latest Funding Round
    $401.26K (USD), Post-IPO

    Nov 2019

  • Employee Count
    70

Products & Services of Aspira Diagnostics

Aspira Diagnostics offers a comprehensive portfolio of products and services, including Pathology Test, Sonography, X-Ray, and Health Packages.

Pathology Test
Diagnostic Testing

Laboratory analysis of blood and samples for health diagnosis

Sonography
Imaging

Ultrasound scans for detecting internal medical conditions

X-Ray
Imaging

Radiographic exams for bone and tissue evaluation

Health Packages
Diagnostic Bundles

Predefined tests for profiles like fever or monsoon-related issues

Funding Insights of Aspira Diagnostics

  • Total Rounds 1
  • Last Round Post-IPO — $401,258
  • First Round $401,258

    (Nov 2019)

All 1 funding rounds of Aspira Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2019$401,258Post-IPO––
–

Board of directors of Aspira Pathlab & Diagnostics Limited (Aspira Diagnostics)

Aspira Pathlab & Diagnostics Limited is the primary company behind Aspira Diagnostics. The board of Aspira Pathlab & Diagnostics Limited currently have 7 directors; the longest-serving is Pankaj Jashwant Shah, appointed in 2016. 25 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Pankaj Jashwant Shah
DIN 02836324
Managing Director01 Aug 201610 yrs 3 moAspira Pathlab & Diagnostics Limited
Avinash Chander Mahajan
DIN 00041661
Director01 Feb 20179 yrs 9 moAspira Pathlab & Diagnostics Limited
Haseeb Ahmad Drabu
DIN 00489888
Director27 Oct 20188 yrsAspira Pathlab & Diagnostics Limited
Nikunj Velji Mange
DIN 08489442
Director29 Aug 20206 yrs 2 moAspira Pathlab & Diagnostics Limited
Manas Rajendra Mengar
DIN 10218206
Director12 Aug 20233 yrs 3 moAspira Pathlab & Diagnostics Limited
Kiran Raghavendra Awasthi
DIN 09066721
Director12 Nov 20251 yrAspira Pathlab & Diagnostics Limited
Vaibhav Odhekar
DIN 05135001
Additional Director23 May 20265 moAspira Pathlab & Diagnostics Limited

People of Aspira Diagnostics

1 people are tracked at Aspira Diagnostics (1 in leadership); the tracked headcount is 70.

NameRoleGroup
CEOLeadership
Premium access

Complete people profiles for Aspira Diagnostics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Aspira Diagnostics

Aspira Diagnostics is a publicly listed company on the BSE with ticker symbol ASPIRA in India, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date12 May 2017
  • Listed onBSE: 540788
  • Listed entityAspira Pathlab & Diagnostics Ltd.
  • Exchange sectorHealth services
  • ISININE500C01017
  • Share price₹120.40 (+4.97% on the day) · 2026-10-14
  • Market capitalisation₹118 Cr
  • Price to earnings21.1
  • EPS (diluted, trailing year)₹-0.44
  • Volume (last session)1,301

Financials of Aspira Diagnostics

Exchange-reported figures of Aspira Pathlab & Diagnostics Limited, the listed company behind Aspira Diagnostics (BSE: ASPIRA).

Financial Highlights

FY 2024-25 · Consolidated
Revenue
₹22.00 Cr
+66.7% YoY
EBITDA
₹3.47 Cr
+389.2% YoY
Profit After Tax
₹2.05 Cr
+176.2% YoY
Net Worth
₹13.37 Cr
+19.2% YoY
Total Assets
₹15.92 Cr
+19.3% YoY
Total Debt
₹1.99 Cr
+17.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2024-25FY 2023-24
Income statement
Revenue22.0013.20
Revenue growth+66.7%-
EBITDA3.47(1.20)
EBITDA margin+15.8%-9.1%
Profit before tax2.02(2.69)
Net profit2.05(2.69)
Net profit margin+9.3%-20.4%
EPS (₹)1.97(2.60)
Balance sheet
Total assets15.9213.34
Net worth13.3711.22
Total debt1.991.70
Cash & bank2.141.38
Net working capital3.812.98
Cash flow
Cash from operations1.831.05
Cash from investing0.120.14
Cash from financing(0.99)(0.95)
ParticularsJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Jun 2023
Revenue5.255.785.416.184.643.822.60
Revenue growth (YoY)+13.2%+51.3%--+78.5%--
Other income0.110.130.090.080.160.080.10
EBITDA0.680.920.611.280.27(0.20)(0.43)
EBITDA margin+13.0%+15.9%+11.3%+20.7%+5.8%-5.2%-16.5%
Depreciation0.370.370.390.360.380.380.39
Interest0.000.000.000.000.000.000.00
Profit before tax0.420.680.311.000.05(0.50)(0.72)
Tax0.000.000.000.000.000.000.00
Net profit0.420.680.311.000.05(0.50)(0.72)
EPS (₹)0.410.660.300.960.05(0.49)(0.70)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue24.9822.0013.2014.4619.5415.218.42
Revenue growth+13.6%+66.7%-8.7%-26.0%+28.5%+80.6%-
EBITDA1.463.52(1.20)1.606.373.52(1.84)
EBITDA margin+5.8%+16.0%-9.1%+11.1%+32.6%+23.1%-21.9%
Profit before tax0.052.07(2.69)(0.09)4.451.39(4.22)
Net profit0.052.10(2.69)(0.09)4.451.39(4.25)
Net profit margin+0.2%+9.6%-20.4%-0.6%+22.8%+9.1%-50.5%
EPS (₹)0.052.01(2.60)(0.09)4.331.34(4.56)
Balance sheet
Total assets16.2715.9713.3416.4316.9910.6012.90
Net worth13.5813.4211.2213.7113.659.084.49
Total debt1.971.991.702.353.061.318.19
Cash & bank1.682.141.382.351.641.191.10
Net working capital2.353.812.984.955.992.701.85
Cash flow
Cash from operations1.451.881.05(0.01)2.035.67(1.87)
Cash from investing(0.80)0.070.140.16(0.51)(0.09)0.24
Cash from financing(1.14)(0.99)(0.95)(0.94)(1.35)(2.17)1.27
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue6.266.176.525.128.095.255.785.41
Revenue growth (YoY)-22.6%+17.5%+12.8%-5.4%+30.9%+13.2%--
Other income0.090.120.140.130.140.110.130.09
Total expenses6.945.836.866.335.904.434.724.64
EBITDA(0.68)0.34(0.34)(1.21)2.190.821.060.77
EBITDA margin-10.9%+5.5%-5.2%-23.6%+27.1%+15.6%+18.3%+14.2%
Depreciation0.460.410.400.380.400.370.370.39
Interest0.110.090.100.100.100.090.090.09
Profit before tax(1.16)(0.04)(0.70)(1.56)1.830.470.730.38
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 17 Nov 2026
ParticularsJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Jun 2023
Revenue5.255.785.416.184.643.822.60
Revenue growth (YoY)+13.2%+51.3%--+78.5%--
Other income0.110.130.090.080.160.080.10
EBITDA0.680.920.611.280.27(0.20)(0.43)
EBITDA margin+13.0%+15.9%+11.3%+20.7%+5.8%-5.2%-16.5%
Depreciation0.370.370.390.360.380.380.39
Interest0.000.000.000.000.000.000.00
Profit before tax0.420.680.311.000.05(0.50)(0.72)
Tax0.000.000.000.000.000.000.00
Net profit0.420.680.311.000.05(0.50)(0.72)
EPS (₹)0.410.660.300.960.05(0.49)(0.70)
ParticularsFY 2024-25FY 2023-24
Revenue22.0013.20
Revenue growth+66.7%-
Other income0.390.42
Total expenses18.5314.40
Employee cost7.336.20
EBITDA3.47(1.20)
EBITDA margin+15.8%-9.1%
Depreciation1.491.54
Interest0.350.37
Profit before tax2.02(2.69)
Tax0.000.00
Net profit2.05(2.69)
Net profit margin+9.3%-20.4%
EPS (₹)1.97(2.60)
ParticularsFY 2024-25FY 2023-24
Equity & liabilities
Share capital16.4316.30
Reserves & surplus(3.06)(5.08)
Shareholders' funds (net worth)13.3711.22
Minority interest0.000.00
Secured loans0.000.00
Unsecured loans1.991.70
Total debt1.991.70
Total liabilities15.9213.34
Assets
Gross block18.3117.20
Net block6.536.79
Capital work in progress0.000.00
Investments0.080.00
Inventories0.510.45
Sundry debtors2.352.24
Cash & bank balances2.141.38
Loans & advances0.360.28
Total current assets5.364.35
Total current liabilities1.551.37
Net working capital3.812.98
Total assets15.9213.34
ParticularsFY 2024-25FY 2023-24
Opening cash0.800.57
Net cash from operating activities1.831.05
Net cash from investing activities0.120.14
Net cash from financing activities(0.99)(0.95)
Net change in cash0.950.24
Closing cash2.141.38
ParticularsFY 2024-25FY 2023-24
Growth
Sales growth+66.7%-
EBITDA growth+389.2%-
PBT growth+9998.0%+9997.0%
Net income growth+176.2%-
Profitability & leverage
Net income margin+9.2%-20.4%
Return on capital employed+11.5%0.0%
Return on net worth+16.5%0.0%
Debt / equity0.150.15
Long-term debt / equity0.090.09
Interest cover17.68-13.50
Efficiency & per share
Fixed asset turnover1.240.77
Inventory turnover45.8329.33
Debtors turnover9.595.89
EPS (₹)1.97(2.60)
Dividend per share (₹)0.000.00
Book value per share (₹)7.035.07
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue6.266.176.525.128.095.255.785.41
Revenue growth (YoY)-22.6%+17.5%+12.8%-5.4%+30.9%+13.2%--
Other income0.090.120.140.130.140.110.130.09
Total expenses6.945.836.866.335.904.434.724.64
EBITDA(0.68)0.34(0.34)(1.21)2.190.821.060.77
EBITDA margin-10.9%+5.5%-5.2%-23.6%+27.1%+15.6%+18.3%+14.2%
Depreciation0.460.410.400.380.400.370.370.39
Interest0.110.090.100.100.100.090.090.09
Profit before tax(1.16)(0.04)(0.70)(1.56)1.830.470.730.38
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue24.9822.0013.2014.4619.5415.218.42
Revenue growth+13.6%+66.7%-8.7%-26.0%+28.5%+80.6%-
Other income0.520.390.420.320.090.200.29
Total expenses23.5218.4814.4012.8613.1711.6910.26
Employee cost0.007.336.205.595.024.034.95
EBITDA1.463.52(1.20)1.606.373.52(1.84)
EBITDA margin+5.8%+16.0%-9.1%+11.1%+32.6%+23.1%-21.9%
Depreciation1.541.491.541.591.641.441.66
Interest0.390.350.370.420.370.891.01
Profit before tax0.052.07(2.69)(0.09)4.451.39(4.22)
Tax0.000.000.000.000.000.000.03
Net profit0.052.10(2.69)(0.09)4.451.39(4.25)
Net profit margin+0.2%+9.6%-20.4%-0.6%+22.8%+9.1%-50.5%
EPS (₹)0.052.01(2.60)(0.09)4.331.34(4.56)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.5716.4316.3016.1816.0815.9914.91
Reserves & surplus(2.99)(3.01)(5.08)(2.47)(2.43)(6.91)(10.42)
Shareholders' funds (net worth)13.5813.4211.2213.7113.659.084.49
Secured loans0.000.000.000.000.000.484.91
Unsecured loans1.971.991.702.353.060.833.28
Total debt1.971.991.702.353.061.318.19
Total liabilities16.2715.9713.3416.4316.9910.6012.90
Assets
Gross block20.5418.3117.2016.8816.8713.4112.91
Net block7.216.536.798.009.587.758.70
Capital work in progress0.000.000.000.000.000.000.00
Investments0.000.130.000.000.000.000.00
Inventories0.700.510.450.400.400.370.28
Sundry debtors1.732.352.242.344.491.700.60
Cash & bank balances1.682.141.382.351.641.191.10
Loans & advances0.470.360.280.770.600.621.31
Total current assets4.585.364.355.867.133.883.29
Total current liabilities2.231.551.370.911.141.181.44
Net working capital2.353.812.984.955.992.701.85
Total assets16.2715.9713.3416.4316.9910.6012.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1.750.800.571.351.19(2.22)(1.87)
Net cash from operating activities1.451.881.05(0.01)2.035.67(1.87)
Net cash from investing activities(0.80)0.070.140.16(0.51)(0.09)0.24
Net cash from financing activities(1.14)(0.99)(0.95)(0.94)(1.35)(2.17)1.27
Net change in cash(0.49)0.950.24(0.79)0.173.41(0.35)
Closing cash1.682.141.382.351.641.191.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.6%+66.7%-8.7%-26.0%+28.5%+80.6%-
EBITDA growth-58.5%+393.3%-175.0%-74.9%+81.0%+291.3%-
PBT growth-97.6%+9998.0%-2888.9%-+220.1%+9998.0%+18.5%
Net income growth-97.6%+178.1%-2888.9%-102.0%+220.1%+132.7%-
Revenue CAGR (3Y)+20.0%+4.0%-4.6%+19.8%+36.8%+51.7%+122.9%
EBITDA CAGR (3Y)-3.0%-17.9%-----10.5%
Profitability & leverage
Net income margin+0.2%+9.4%-20.4%-0.6%+22.8%+9.1%-50.5%
Return on capital employed+1.6%+11.7%0.0%0.0%+17.6%+11.5%0.0%
Return on net worth+0.3%+16.9%0.0%0.0%+23.1%+15.2%0.0%
Debt / equity0.150.150.160.200.190.701.47
Long-term debt / equity0.080.090.110.150.130.370.84
Interest cover-487.5017.24-13.504,200.007.8242.79-28.86
Efficiency & per share
Fixed asset turnover1.291.240.770.861.291.160.69
Inventory turnover41.2945.8331.0636.1550.7546.8030.07
Debtors turnover12.259.595.764.236.3113.2312.03
EPS (₹)0.052.01(2.60)(0.09)4.331.34(4.56)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)7.097.085.077.607.643.29(1.21)

Timeline of Aspira Diagnostics

3 dated milestones of Aspira Diagnostics across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded Aspira Diagnostics is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $401K.

Similar companies to Aspira Diagnostics

Aspira Diagnostics has 3 listed similar companies in our database, 3 of them funded. They include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
lalpathlabs.com1949Gurugram, India$13.9M8,279
Chain of pathology and radiology labs
redcliffelabs.com2018Noida, India$116.42M2,104
Home-based diagnostic tests are booked via an online platform.
sterlingaccuris.com2015Ahmedabad, India$41.69M1,229
Pathology diagnostic services are offered via a chain of labs.
Premium access

Detailed similar companies of Aspira Diagnostics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Aspira Diagnostics

The website of Aspira Diagnostics (aspiradiagnostics.com) receives about 1.8K visits a month.

  • Monthly visits
    1.8K

    ▲ 14% vs previous month

Top companies in Diagnostics Laboratories

3 companies that operate in the same segment as Aspira Diagnostics (Diagnostics Laboratories) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Diagnostic testing centers for pathology and health screenings are operated.
1996Mumbai, Maharashtra, IndiaUSD 63.59 MUSD 90.17 M1,979
Chain of pathology and radiology labs
1949Gurugram, Haryana, IndiaUSD 13.9 MUSD 294.49 M5,310
Home-based diagnostic tests are booked via an online platform.
2018Noida, Uttar Pradesh, IndiaUSD 116.42 MUSD 52.45 M2,334
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Aspira Diagnostics

Premium access

Complete news archive for Aspira Diagnostics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Aspira Diagnostics

Aspira Diagnostics was founded in 2015 and raised its 1st funding round 4 years after it was founded.

Aspira Diagnostics is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Chander Puri is the CEO of Aspira Diagnostics, as recorded in our data.

Aspira Diagnostics has 70 employees.

The primary company behind Aspira Diagnostics, Aspira Pathlab & Diagnostics Limited, reported revenue of ₹25.50 Cr for FY 2026, up 14% year on year.

Aspira was founded in 2015 and is based in Mumbai, India. The company operates as a chain of pathology labs focused on diagnostic services. Core activities include laboratory testing and pathology diagnostics, with operations centered in the healthcare sector. The domain aspiradiagnostics.com is used for its online presence. Leadership is provided by CEO Chander Puri.

Aspira Diagnostics's top competitors include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics.

Aspira Diagnostics offers Pathology Test, Sonography, X-Ray, and Health Packages.

Yes, Aspira Diagnostics is publicly traded on BSE under the ticker symbol ASPIRA.

Aspira Diagnostics operates through Aspira Pathlab & Diagnostics Limited.

The legal entities of Aspira Diagnostics currently have 9 directors, including Manas Rajendra Mengar, Vaibhav Odhekar, Kiran Raghavendra Awasthi and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available